ID   769-P
AC   CVCL_1050
SY   769P; 769-p
DR   CLO; CLO_0001485
DR   EFO; EFO_0002099
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; CRL-1933
DR   BioSample; SAMN03473275
DR   CCLE; 769P_KIDNEY
DR   CCRID; 3111C0001CCC000333
DR   CCRID; 3131C0001001200020
DR   CCRID; 3142C0001000000087
DR   CCTCC; GDC0103
DR   Cell_Model_Passport; SIDM00803
DR   ChEMBL-Cells; CHEMBL3308705
DR   ChEMBL-Targets; CHEMBL1075385
DR   CLS; 300106/p490_769-P
DR   Cosmic; 687935
DR   Cosmic; 801355
DR   Cosmic; 910922
DR   Cosmic; 982280
DR   Cosmic; 1779197
DR   Cosmic; 2520640
DR   Cosmic-CLP; 910922
DR   GDSC; 910922
DR   GEO; GSM374479
DR   GEO; GSM827256
DR   GEO; GSM886844
DR   GEO; GSM887908
DR   GEO; GSM1669571
DR   IGRhCellID; 769P
DR   IZSLER; BS TCL 123
DR   KCB; KCB 2013031YJ
DR   LINCS_LDP; LCL-1772
DR   Wikidata; Q54604830
RX   PubMed=721102;
RX   PubMed=1010528;
RX   PubMed=6244232;
RX   PubMed=17178751;
RX   PubMed=20215515;
RX   PubMed=22460905;
RX   PubMed=22949125;
RX   PubMed=25485619;
RX   PubMed=27397505;
RX   PubMed=27993170;
RX   PubMed=28196595;
RX   PubMed=28489074;
RX   PubMed=30894373;
WW   http://tcpaportal.org/mclp/
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Part of: COSMIC cell lines project.
CC   Part of: MD Anderson Cell Lines Project.
CC   Doubling time: 35 hours (PubMed=721102).
CC   Microsatellite instability: Instable (MSI-low) (Sanger).
CC   Omics: Array-based CGH.
CC   Omics: Deep exome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=1.32%; Native American=0%; East Asian, North=3.45%; East Asian, South=0%; South Asian=0%; European, North=68.23%; European, South=27% (PubMed=30894373).
ST   Source(s): ATCC; CLS; Cosmic-CLP; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 11,12
ST   D13S317: 10,14
ST   D16S539: 9,13
ST   D18S51: 14,17
ST   D21S11: 28,30
ST   D3S1358: 16
ST   D5S818: 12
ST   D7S820: 10,11
ST   D8S1179: 12,16
ST   FGA: 20,22
ST   Penta D: 12,16
ST   Penta E: 7,18
ST   TH01: 6,9.3
ST   TPOX: 8,11
ST   vWA: 18
DI   NCIt; C9385; Renal cell carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Female
AG   63Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 24-05-19; Version: 23
//
RX   PubMed=721102; DOI=10.1007/BF02617972;
RA   Williams R.D., Elliott A.Y., Stein N., Fraley E.E.;
RT   "In vitro cultivation of human renal cell cancer. II. Characterization
RT   of cell lines.";
RL   In Vitro 14:779-786(1978).
//
RX   PubMed=1010528; DOI=10.1007/BF02797460;
RA   Williams R.D., Elliott A.Y., Stein N., Fraley E.E.;
RT   "In vitro cultivation of human renal cell cancer. I. Establishment of
RT   cells in culture.";
RL   In Vitro 12:623-627(1976).
//
RX   PubMed=6244232;
RA   Williams R.D.;
RT   "Human urologic cancer cell lines.";
RL   Invest. Urol. 17:359-363(1980).
//
RX   PubMed=17178751; DOI=10.1093/nar/gkl1030;
RA   Fiegler H., Geigl J.B., Langer S., Rigler D., Porter K., Unger K.,
RA   Carter N.P., Speicher M.R.;
RT   "High resolution array-CGH analysis of single cells.";
RL   Nucleic Acids Res. 35:E15-E15(2007).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=22949125; DOI=10.1002/ijc.27822;
RA   Pawlowski R., Muhl S.M., Sulser T., Krek W., Moch H., Schraml P.;
RT   "Loss of PBRM1 expression is associated with renal cell carcinoma
RT   progression.";
RL   Int. J. Cancer 132:E11-E17(2013).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H.,
RA   Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y.,
RA   Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D.,
RA   Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D.,
RA   Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S.,
RA   Zhang Z.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M.,
RA   Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M.,
RA   Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A.,
RA   Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=27993170; DOI=10.1186/s12943-016-0565-8;
RA   Brodaczewska K.K., Szczylik C., Fiedorowicz M., Porta C.,
RA   Czarnecka A.M.;
RT   "Choosing the right cell line for renal cell cancer research.";
RL   Mol. Cancer 15:83-83(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P.,
RA   Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=28489074; DOI=10.1038/ncomms15165;
RA   Sinha R., Winer A.G., Chevinsky M., Jakubowski C., Chen Y.-B., Dong Y.,
RA   Tickoo S.K., Reuter V.E., Russo P., Coleman J.A., Sander C.,
RA   Hsieh J.J., Hakimi A.A.;
RT   "Analysis of renal cancer cell lines from two major resources enables
RT   genomics-guided cell line selection.";
RL   Nat. Commun. 8:15165-15165(2017).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//